Fretland A J, Doll M A, Gray K, Feng Y, Hein D W
Department of Pharmacology and Toxicology, University of North Dakota School of Medicine and Health Sciences, Grand Forks 58202-9037, USA.
Toxicol Appl Pharmacol. 1997 Feb;142(2):360-6. doi: 10.1006/taap.1996.8036.
An acetylator polymorphism has been described in the mouse and the inbred strains C3H/HeJ and A/HeJ constitute rapid and slow acetylators, respectively. The NAT1, NAT2, and NAT3 genes from C3H/HeJ and A/HeJ acetylator inbred mouse strains were amplified using the polymerase chain reaction, cloned into the plasmid vector pUC19, and sequenced. They were then subcloned into the prokaryotic expression vector pKK223-3 and expressed in Escherichia coli strain JM105. The 870-bp nucleotide coding region of NAT1 and NAT3 did not differ between the rapid and slow acetylator mouse strains, or from that of previously published mouse NAT1 and NAT3 sequences. However, NAT2 did differ between the rapid and slow acetylator strains with an A296 T transition which causes a (Asn99-->Ile) substitution in the deduced amino acid sequence. Recombinant NAT1, NAT2, and NAT3 proteins catalyzed N-, O-, and N,O-acetyltransferase activities. NAT3 catalyzed aromatic amine N-acetyltransferase activities at very low rates, which confirms a previous study. Apparent K(m) and Vmax kinetic constants for N-acetylation were 5- to 10-fold lower for recombinant mouse NAT1 than NAT2. Intrinsic clearances for recombinant mouse NAT1- and NAT2-catalyzed N-acetylation of aromatic amine carcinogens were comparable. Both recombinant mouse NAT1 and NAT2 catalyzed the metabolic activation of N-hydroxyarylamine (O-acetylation) and N-hydroxyarylamide (N,O-acetylation) carcinogens. Recombinant mouse NAT3 catalyzed N,O-acetylation at very low rates, while O-acetylation was undetectable. No difference was observed between rapid and slow acetylator recombinant NAT2 proteins to activate aromatic amines by O- or N,O-acetylation, in substrate specificity, expression of immunoreactive protein, electrophoretic mobility, or N-acetyltransferase Michaelis-Menten kinetic constants. However, the slow acetylator recombinant NAT2 protein was over 10-fold less stable than rapid acetylator recombinant NAT2. These studies demonstrate metabolic activation and deactivation by recombinant mouse NAT1, NAT2, and NAT3 proteins and confirm and extend previous studies on the molecular basis for the acetylation polymorphism in the mouse.
小鼠中已描述了一种乙酰化酶多态性,近交系C3H/HeJ和A/HeJ分别构成快速和慢速乙酰化酶。使用聚合酶链反应扩增来自C3H/HeJ和A/HeJ乙酰化酶近交小鼠品系的NAT1、NAT2和NAT3基因,克隆到质粒载体pUC19中并进行测序。然后将它们亚克隆到原核表达载体pKK223-3中,并在大肠杆菌JM105菌株中表达。NAT1和NAT3的870个碱基对的核苷酸编码区在快速和慢速乙酰化酶小鼠品系之间没有差异,也与先前发表的小鼠NAT1和NAT3序列不同。然而,NAT2在快速和慢速乙酰化酶品系之间存在差异,有一个A296T转换,这在推导的氨基酸序列中导致(Asn99→Ile)取代。重组NAT1、NAT2和NAT3蛋白催化N-、O-和N,O-乙酰转移酶活性。NAT3以非常低的速率催化芳香胺N-乙酰转移酶活性,这证实了先前的一项研究。重组小鼠NAT1的N-乙酰化的表观K(m)和Vmax动力学常数比NAT2低5至10倍。重组小鼠NAT1和NAT2催化芳香胺致癌物N-乙酰化的内在清除率相当。重组小鼠NAT1和NAT2都催化N-羟基芳胺(O-乙酰化)和N-羟基芳酰胺(N,O-乙酰化)致癌物的代谢活化。重组小鼠NAT3以非常低的速率催化N,O-乙酰化,而未检测到O-乙酰化。在通过O-或N,O-乙酰化激活芳香胺方面,快速和慢速乙酰化酶重组NAT2蛋白在底物特异性、免疫反应性蛋白表达、电泳迁移率或N-乙酰转移酶米氏动力学常数方面没有差异。然而,慢速乙酰化酶重组NAT2蛋白的稳定性比快速乙酰化酶重组NAT2低10倍以上。这些研究证明了重组小鼠NAT1、NAT2和NAT3蛋白的代谢活化和失活作用,并证实和扩展了先前关于小鼠乙酰化多态性分子基础的研究。